Aadi Bioscience, Inc. (NASDAQ:AADI) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET
Company Participants
Andrew Quan - VP, Business Development & Corporate Strategy
Neil Desai - Founder, President, CEO, Secretary & Director
Brendan Delaney - COO
Loretta Itri - Chief Medical Officer
Scott Giacobello - CFO & Treasurer
Conference Call Participants
Boris Peaker - Cowen and Company
Ahu Demir - Ladenburg Thalmann & Co.
Joseph Catanzaro - Piper Sandler & Co.
Jiale Song - Jefferies
Operator
Greetings, and welcome to the Aadi Bioscience, Inc. First Quarter 2021 Earnings Conference Call. [Operator Instructions].
It is now my pleasure to introduce your host, Andrew Quan, VP of Business Development and Corporate Strategy. Thank you. You may begin.
Andrew Quan
I would like to welcome everyone to the first Aadi Bioscience Quarterly Results Call for Q1 2022. With us on the call today from Aadi Bioscience are Neil Desai, Founder, President and CEO, who will give a quick overview of the quarter; Brendan Delaney, Chief Operating Officer, who will provide early commercial uptake commentary and metrics; Dr. Loretta M. Itri, Chief Medical Officer, who will walk us through clinical development priorities and forthcoming updates; and Scott Giacobello, Chief Financial Officer, who will provide an overview of our financials this quarter.
Before we get started, I would like to remind everyone that statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks uncertainties and other factors, including those set forth in the Risk Factors section of our annual and quarterly filings with the Securities and Exchange Commission, and can be found at www.sec.gov, or on our website at www.aadibio.com.
In addition, any forward-looking statements made on this call represent our views only as of today, May 12, 2022, and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements.
With that, let me turn the call over to Neil.
Neil Desai
Thank you, Andrew. Good morning, everyone, and thank you for joining. The first quarter of 2022 was transformative for Aadi Bioscience. We successfully transitioned into a fully integrated biopharmaceutical company, commercializing and launching our first product, FYARRO, an albumin-bound mTOR inhibitor, also known as napsurolomus, for advanced malignant PEComa, on February 22 of this year.